Abstract This paper presents an analysis of Pfizer, the largest American pharmaceutical company, the company's strategic priorities and an analysis of an acquisition. The paper includes a SWOT analysis of the company's strengths and weaknesses and the opportunities and threats it faces.
From the Paper "Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo and markets such well-known medications as Celebrex and Viagra ..."
Abstract The paper discusses the pharmaceutical giant, Pfizer, as a marketing powerhouse. This report overviews some of its key products and tactics it uses in marketing them to consumers, physicians and managed care organizations.
From the Paper "Marketing powerhouse Pfizer began back in ? as a chemicals company. Today it is a billion global enterprise and is one of the top pharmaceutical companies in the world. Pfizer's core products include Aricept Alzheimer's disease, Celebrex pain, Diflucan infection, Lipitor high cholesterol, Neurontin pain and epilepsy, Norvasc high blood pressure, Viagra erectile dysfunction, Xalatan glaucoma, Zithromax infection, Zoloft depression and Zyrtec allergy. The ultimate goal of Pfizer's marketing strategy is to increase drug sales which for prescription pharmaceuticals can only be accomplished by increased prescription writing."
Tags:Pfizer, pharmaceutical marketing, direct to consumer advertising, physician detailing, managed care organizations
Abstract This paper explains the history, management and organization of Pfizer Pharmaceuticals and its industry. The author reports that accounting ratios are the key basis for the financial analysis of this company based on data from 2005, 2006 and 2007. Computations are included in the paper. The paper indicates that the drop in profitability and the declining liquidity, which is probably stemming from cash problems, may hinder potential investors from investing in this organization.
Table of Contents:
Introduction: History on Pfizer Pharmaceuticals
Management Level of the Pfizer Incorporation
Profile of Pfizer Pharmaceuticals
Financial Analysis of Pfizer Incorporation
Table: 2005, 2006 and 2007 Accounting Ratios
Liquidity of Pfizer Incorporation
Asset Utilization of Pfizer Incorporation
Profitability of Pfizer Incorporation
Stability and Debt Management of Pfizer Incorporation
Investors Ratios
Computation of Accounting Ratios
Liquidity Ratios
Cash Conversional Cycle
Profitability Ratios
Stability and Debt Management
Investors Ratios
Final Thought - Shareholder Value
From the Paper "Another important element of the financial position of the company is the cash flow of the company. Indeed the Cash Conversional Cycle was computed in section 1.2 of this paper to outline such area. The ratios express the length of time, in days, which a firm takes to convert the resource inputs into cash flow. A steady decrease in this matrix is noted over the three years examined from 271 days to 183 days. This is a positive element for the liquidity of the organization because management is more effective in translating the revenue transactions into cash."
Abstract This paper examines how Pfizer is one of the most successful pharmaceutical companies in existence and how much, if not most, of Pfizer's success is due to the corporation's marketing genius, which is considered to be among the best in the industry. It looks at how Pfizer also has one of the best safety records in the industry, which helps in gaining investors and trust in the company. It also explores how, unlike most large corporations, Pfizer draws revenue from a limited number of products.
Outline
Company Structure and Marketing Strategies
Marketing Strengths
Threats
From the Paper "The marketing principles utilized by Pfizer guides every aspect of the corporation's business. There are five main principles that are fundamental to Pfizer's business practices. First, the work conducted by Pfizer is grounded in science. With solid clinical research as a foundation, Pfizer's marketing group uses its credibility and knowledge to develop important relationships within the medical community. Second, Pfizer takes an integrated approach to its marketing strategies. Innovation is promoted through the encouragement of teamwork within and across marketing groups. This also allows Pfizer to respond flexibly and promptly to changes in the market."
Abstract This paper explains that Pfizer has built a strong business around product development and product marketing that leaves its competitors at a disadvantage in their efforts to mimic its operations. The author points out that the Ansoff Matrix is an excellent tool to weigh various potential marketing strategies. The paper relates that ideally marketing strategies should be linked to overall corporate strategy and organizational objectives as outlined by the enterprise's executive leadership. The author indicates that another growth option is to expand organically from within Pfizer. The paper concludes that, because of Pfizer's success with Lipitor, which Pfizer markets worldwide, the company should continue to capitalize on this product by creating a generic Lipitor line extension. The author continues with an analysis of this marketing strategy.
Table of Contents:
Overview
Strategy Development
Ansoff's Growth Matrix
Synthesis of Objectives
Growth Strategies
Option One
Option Two
Target Market
Positioning
Product
Placement (Distribution)
Pricing
Promotion
Conclusion
From the Paper "As soon as Pfizer is forced to go to market with its own generic version of Lipitor at reduced prices, the first year sales objective is to level Lipitor sales at $5-7 billion globally and to reach generic Lipitor sales of $3 to 5 billion. In so doing, the majority of Lipitor's research and development expenses will maintain substantial revenues. Current prices for Lipitor average $77 for a 30 day supply (Pfizer, 2005). The target price for the generic version should be $45 for a comparable supply."
Abstract This paper takes a look at how the pharmaceutical company Pfizer has been quite effective at utilizing marketing strategy based market development to expand its revenue streams and extend the useful life of its existing products. The paper maintains that Pfizer's sales and marketing division is one of the drug industries best and has been a strong contributor to creating one of the most pathological advertising establishments in the United States. The paper uses the Ansoff matrix as a tool to assess Pfizer's marketing strategies in relation to the general drug market. The paper concludes that Pfizer owes its success to its vast resources, global distribution and channel technology, and brand equity.
Outline:
Introduction
Gap Analysis
Ansoff's Matrix-Strategic Planning
Recommended Solutions
Conclusion
From the Paper "There are several strategies to accomplish growth. One of the easiest from an operational standpoint is to simply acquire or merge with another company which is inline with Ansoff's market or product development strategy. The exact nature of the strategy is dependent upon the character of the businesses being acquired or merged with. Mergers and acquisitions (M&A) provide companies with an instant expanded market and a new product or product line as well as, potentially, a completely new industry. If the M&A target is a company that focuses on a different market or market segment this would be a strategy based on market development because the primary company would be moving into what is, in effect, according to Ansoff, a new market."
Tags: drug, product, chemistry, pill, Ansoff, matrix, medicine
Abstract This paper provides a brief insight into Pfizer Inc., a giant in the Pharmaceutical Sector, which is traded on the New York Stock Exchange and whose principle activities include the research and manufacturing of prescription medicines for human and veterinary applications on a global scale. It examines how Pfizer stock has been on a downtrend since mid-year 2001 after a boom in the biotechnology sector which is closely related to the pharmaceutical sector. It analyzes whether Pfizer stock is a good buy at such a low price, or whether it is better left alone for fear that it will fall further. It attempts to determine this by considering their overall financial health and by a comparison of the price/earning ratios to the averages for the sector in which it operates and to the market as a whole.
From the Paper "Pfizer is subject to several risks associated with the industry in general. Changes in the health care environment, litigation costs, competition, legislative changes, changes in Medicare and Medicaid payments and foreign exchange rates all have the potential to effect the profitability of company in the future (Pfizer, Inc., 2003a). The Warner-Lambert merger caused Pfizer to make several accounting changes (Pfizer, Inc., 2003a). Pfizer is subject to many risks. However, it has formal risk management strategies with a proven track record in mitigating risks in the past. Pfizer has multiple income streams to cushion against the loss of one income stream, such as the loss of licenses from the FDA, as happened when their product Rezulin was pulled from the market (Pfizer, Inc., 2003a). In addition, Pfizer is constantly conducting research and development to bring more products to market."
This paper is a risk analysis of Pfizer, Inc. and the pharmaceutical industry including its direct competitors: Bayer AG, Merck & Co., Novartis AG, Abbott Labs and Eli Lilly.
Abstract This paper explains that Pfizer and all five of its direct competitors essentially face many of the same risks such as the tendency for the marketplace to discourage the use of new medicines because of their higher costs. The author points out that the safety of products and proper usage by consumers are always concerns as demonstrated by the problems facing Bayer and Merck and, now, potentially, by Pfizer with Celebrex. The paper concludes that Pfizer is unique from its competitors and remains the leading pharmaceutical company because of its effective risk and resource management of the company's extraordinary portfolio management practices, security of the day-to-day management of resources and its research and development.
From the Paper "The third goal, corporate social responsibility, means putting people and communities first and preserving and protecting the environment. It also means being sensitive to the needs of Pfizer's colleagues, and evaluating the company from a critical point of view. Over the past four years, Pfizer has almost tripled in size, from about 45,000 colleagues worldwide to over 122,000. In 2003, Pfizer created a global corporate citizenship coordinating team. The goal of this group is to help unify Pfizer's approach to corporate citizenship across many countries and cultures, through membership in organizations that promote responsible business practices internationally. Some of the initiatives that have been explored are the reduction of carbon monoxide emissions and supplying global energy through cleaner sources. This final goal is a symbol of Pfizer's commitment to strengthen leadership and become more responsive."
Abstract This paper explains that Pfizer is a multi-billion dollar pharmaceutical company that produces and distributes several blockbuster pharmaceutical products. It claims that currently the world's leading pharmaceutical product is Lipitor, one of Pfizer's products. Lipitor has been the target of several patent challenges and is scheduled to move off patent in any regard within the next several years. It explores how Pfizer will be affected by this and expands on its business plans.
From the Paper "Pfizer is a multi-billion dollar pharmaceutical company that produces and distributes several blockbuster pharmaceutical products. Currently the world's leading pharmaceutical product is Lipitor, one of Pfizer's products. Lipitor has been the target of several patent challenges and is scheduled to move off patent in any regard within the next several years. Pfizer is recommended to develop its own generic product, based on Lipitor, as a way to offset a percentage of the sales that are certain to be affected by other generic drug manufacturers. By developing this line extension of its blockbuster Lipitor product, Pfizer can continue to generate revenue off its substantial investment in research and development required for Lipitor without cannibalizing sales of its remaining Lipitor business."
Abstract This paper discusses how Pfizer has developed a very integrated manufacturing and distribution network that has allowed it to capitalize on its brand image as a leading pharmaceutical company. The paper labels Pfizer's sales and marketing division as one of the best in the industry. The paper concludes that because of Pfizer's success with Lipitor, which it markets worldwide, the company should continue to capitalize on this product by creating a generic Lipitor line extension.
Outline:
Overview
Strategy Development
Ansoff's Growth Matrix
Synthesis of Objectives
Growth Strategies
Conclusion
From the Paper "For the pharmaceutical industry, the intensity of the competitive forces at play is extremely high because the risks at stake are considerable. These large stakes are due to the nature of the industry where huge sums of money must be spent to simply discover new products, while additional huge sums then must be committed to develop them, seek regulatory approval, and then actively market them (Miller, 2003, para.3). With such huge sums of investment dollars required for almost every product brought to market, the competitive forces surrounding the industry are extreme."
Abstract This paper provides an insight into the two pharmaceutical companies Pfizer Inc. and Merck with an emphasis on their marketing strategies. It outlines the companies? products, services and position in their industry and then provides a comparative analysis using the four Ps of marketing.
Outline
Introduction
Company Analysis - Pfizer Inc.
Line of Business and Sales and Profit Trends
The Specific Target Market(S) Sought
Company Brands, Manner of Distribution, Promotion Methods and Pricing
The Differential Advantages/Strengths of the Firm
International Performance
Company Analysis - Merck
Line of Business and Sales and Profit Trends
The Specific Target Market(S) Sought
Company Brands, Manner of Distribution, Promotion Methods and Pricing
The Differential Advantages/Strengths of the Firm
International Performance
Comparison
Web Sites
Describe Each Site
Strengths and Weaknesses of Each Site
Specific Sections
Improvement of Both the Sites
Conclusion
Bibliography
Appendix
From the Paper "Unlike other firms, Pfizer's main business focus had been to improve its products and to extend its product line. Over the years, analysts find that Pfizer has spent much more on currency of its research and development as compared to business development and strategy. For example one analyst comments on Pfizer's strategy: "McKinnell is one of the primary architects of the acquisition strategy that has supercharged Pfizer's growth. So it's startling to hear him argue that the company's acquisition days are over. Despite the fact that Pfizer commands only 11% of the global pharmaceutical market, its growth, he declares, now lies in R&D, not M&A. "This Company's future will be quite different," McKinnell says. "People tend to evaluate research looking out the back window, not the front. And the '90s were really unusual." [Simons, 2003]. For this reason it has leverage over other companies. However with the emergence of new prescription drugs and mandates in biomedical fields other companies like Merck, Pharmacia as well as Eli Lilly have been focusing their investments in these areas as well [See Appendix]. "
Tags: promotion, pricing, drugs, competition, distribution
Abstract This paper explains that Pfizer is in a very good financial situation as indicated in the Tables of Solvency and Profitability Measures. The author relates the working capital shows that the asset value is increasing at a greater pace than the liabilities; however, if the the current ratio in 2002 is compared to 2001, there is a slight decrease in its values, which shows us that the current liabilities have slightly increased in value. The paper states that the only possible problem could appear from the company's tendency to finance its assets from long-term debt, but Pfizer has the power to support interest payment from its income.
From the Paper "Net income has increased by 17 % from 2001 to 2002 and this may seem little if we look at the increase of net income from 2000 to 2001 (109 %!). If we analyze closer the Statement of Income, we will find out however that in 2000, income was low due to merger costs that accounted for $3,223 million, while in 2001 and 2002, these costs are negligible reported to earnings. Thus, we will report or findings by comparing the revenues from 2002 and 2001 and noting that the company has steadily increased its sales and net income, showing no downturn to recession."
Abstract This report examines and analyzes the company Pfizer in its position as a leading worldwide pharmaceutical company. The paper evaluates its risk position and total stock return in comparison to five of its direct competitors: Bayer AG, Merck & Co., Abbott Labs, Novartis and Eli Lilly. It also discusses the significance of Pfizer's partnerships with Pharmacia and Warner Lambert and the significance of these relationships on the company's overall financial performance.
From the Paper "Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures and markets leading prescription medicines for humans and animals, as well as many of the world's best known consumer healthcare products. Everything done at Pfizer is a reflection of the company's mission, a commitment to serving the total health-care continuum. Fine portfolio management practices help inform company executives, the day to day management of resources, allocation of employees, uncertainty in drug development and competitive pressures call for an unprecedented in-depth analysis monitoring the company's general risk exposure."
Abstract This paper analyzes the US medical giant, Pfizer Inc. According to this paper, Pfizer Inc. is one of the leading pharmaceutical companies in the U.S. This paper reviews the company's place in the industry and their stock dividends.
From the Paper "Pfizer is a U.S. based pharmaceutical company, which opened its doors 156 years ago in 1849 with a compound that was proven to take care of parasitic worms. There were two co-founders, Charles Pfizer and his cousin Charles Erhart. Both had come from Germany in the hopes of starting a business together. They had no idea that what they would leave behind would end up being one of the largest pharmaceutical companies in the nation ("Exploring our History", 2005). Industry Analysis Pfizer participates in an industry coded and named by the United States Department of Labor. As such they do business in Division D: Manufacturing - Major Group 28: Chemicals and Allied Products. Specifically Pharmaceutical Preparation coded 2834. Any company in this category produces, manufactures, "fabricates or processed pharmaceutical drugs in preparation for human or veterinary consumption" ("SIC Description for 2834", 2005)."
Abstract This paper takes a look at Pfizer's Animal Health Group, which must develop a solution that allows it to maintain its brand reputation and profitability in its animal health business despite growing price pressure in the cattle market. The paper discusses the strengths and weaknesses of Pfizer.
Outline:
Problem Statement
Situation Analysis
Major Strategic Alternatives
Decision Criteria
Analysis of Alternatives
Recommended Solution
From the Paper "A final alternative is to help ranchers build value for their beef. Currently, beef is a commodity product where cheaper is better. Experts predict that the beef industry will engage in more marketing and more development of ready-to-eat products in the near future, and perhaps consumers will be interested in branded beef that they know is of a high quality (Cravens and Piercy, 509). The advantage of this strategy is that it could ease pressure on beef prices and even force ranchers to use Pfizer's premium products to meet the new standards. The disadvantage is that there is a risk that consumers and meatpackers won't be interested in the program."
